These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 21574240)

  • 1. Another view on the analysis of cardiovascular morbidity/mortality trials.
    Rosenkranz GK
    Pharm Stat; 2011; 10(3):196-202. PubMed ID: 21574240
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The analysis of competing events like cause-specific mortality--beware of the Kaplan-Meier method.
    Verduijn M; Grootendorst DC; Dekker FW; Jager KJ; le Cessie S
    Nephrol Dial Transplant; 2011 Jan; 26(1):56-61. PubMed ID: 21059831
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Designing phase II studies in cancer with time-to-event endpoints.
    Owzar K; Jung SH
    Clin Trials; 2008; 5(3):209-21. PubMed ID: 18559409
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chronic kidney disease and mortality and morbidity among patients with established cardiovascular disease: a West of Ireland community-based cohort study.
    Glynn LG; Reddan D; Newell J; Hinde J; Buckley B; Murphy AW
    Nephrol Dial Transplant; 2007 Sep; 22(9):2586-94. PubMed ID: 17452408
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recommendations to meet statistical challenges arising from endpoints beyond overall survival in clinical trials on chronic myeloid leukemia.
    Pfirrmann M; Hochhaus A; Lauseker M; Saussele S; Hehlmann R; Hasford J
    Leukemia; 2011 Sep; 25(9):1433-8. PubMed ID: 21597465
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Meta-analysis of the Italian studies on short-term effects of air pollution].
    Biggeri A; Bellini P; Terracini B;
    Epidemiol Prev; 2001; 25(2 Suppl):1-71. PubMed ID: 11515188
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of long-term exposure to traffic-related air pollution on respiratory and cardiovascular mortality in the Netherlands: the NLCS-AIR study.
    Brunekreef B; Beelen R; Hoek G; Schouten L; Bausch-Goldbohm S; Fischer P; Armstrong B; Hughes E; Jerrett M; van den Brandt P
    Res Rep Health Eff Inst; 2009 Mar; (139):5-71; discussion 73-89. PubMed ID: 19554969
    [TBL] [Abstract][Full Text] [Related]  

  • 8. What we want versus what we can get: a closer look at failure time endpoints for cardiovascular studies.
    Song R; Cook TD; Kosorok MR
    J Biopharm Stat; 2008; 18(2):370-81. PubMed ID: 18327727
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of a binary composite endpoint with missing data in components.
    Quan H; Zhang D; Zhang J; Devlamynck L
    Stat Med; 2007 Nov; 26(26):4703-18. PubMed ID: 17431851
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A linear rank test for use when the main interest is in differences in cure rates.
    Gray RJ; Tsiatis AA
    Biometrics; 1989 Sep; 45(3):899-904. PubMed ID: 2790128
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Methods for analysis of censored tumor growth delay data.
    Stuschke M; Budach V; Bamberg M; Budach W
    Radiat Res; 1990 May; 122(2):172-80. PubMed ID: 2336463
    [TBL] [Abstract][Full Text] [Related]  

  • 12. General right censoring and its impact on the analysis of survival data.
    Lagakos SW
    Biometrics; 1979 Mar; 35(1):139-56. PubMed ID: 497332
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II cancer clinical trials with a one-sample log-rank test and its corrections based on the Edgeworth expansion.
    Sun X; Peng P; Tu D
    Contemp Clin Trials; 2011 Jan; 32(1):108-13. PubMed ID: 20888929
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Semiparametric analysis of survival data with left truncation and dependent right censoring.
    Jiang H; Fine JP; Chappell R
    Biometrics; 2005 Jun; 61(2):567-75. PubMed ID: 16011706
    [TBL] [Abstract][Full Text] [Related]  

  • 15. "Just Another Statistic".
    Machtay M; Glatstein E
    Oncologist; 1998; 3(3):III-IV. PubMed ID: 10388105
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Semi-parametric and non-parametric methods for clinical trials with incomplete data.
    O'Brien PC; Zhang D; Bailey KR
    Stat Med; 2005 Feb; 24(3):341-58. PubMed ID: 15547952
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analyses of cumulative incidence functions via non-parametric multiple imputation.
    Ruan PK; Gray RJ
    Stat Med; 2008 Nov; 27(27):5709-24. PubMed ID: 18712779
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Joint modeling of progression-free survival and death in advanced cancer clinical trials.
    Dejardin D; Lesaffre E; Verbeke G
    Stat Med; 2010 Jul; 29(16):1724-34. PubMed ID: 20572123
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Semiparametric estimation in copula models for bivariate sequential survival times.
    Lawless JF; Yilmaz YE
    Biom J; 2011 Sep; 53(5):779-96. PubMed ID: 21887793
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Unconventional end points in cardiovascular clinical trials: should we be moving away from morbidity and mortality?
    Cohn J; Cleland JG; Lubsen J; Borer JS; Steg PG; Perelman M; Zannad F
    J Card Fail; 2009 Apr; 15(3):199-205. PubMed ID: 19327621
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.